Global Abiraterone Acetate Drugs Market

Abiraterone Acetate Drugs Comprehensive Study by End Users (Hospitals, Specialized Clinics, Diagnostic Centres), Treatment (Chemotherapy, Hormone Therapy, Clinical Trials, Radiotherapy, Others), Distribution Channel (Online {Company Website, E-Commerce Website}, Offline {Hospital Pharmacy, Retail Stores}), Dosage Form (Film-Coated Tablet, Uncoated Tablet) Players and Region - Global Market Outlook to 2026

Abiraterone Acetate Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Abiraterone is a drug that is used in conjunction with prednisone to treat prostate cancer that has progressed to other areas of the body. Androgen biosynthesis inhibitors, such as abiraterone, are a kind of drug. It works by lowering the body's level of specific hormones. It is used in the treatment of metastatic castration-resistant prostate cancer and metastatic high-risk castration sensitive prostate cancer in combination with a corticosteroid. It should be administered either after the testicles have been removed or in conjunction with a gonadotropin-releasing hormone mimic.This growth is primarily driven by Increase in Incidence of Prostate Cancer in Men.

Globally, a noticeable market trend is evident Rapid Development of Prednisolone. Major Players, such as Roche Holding AG (Switzerland), Merck & Co. (United States), Dr. Reddy's Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), Sigma-Aldrich (United States), Johnson & Johnson (United States), Cipla Ltd. (India), ScinoPharm (Taiwan), Teva Pharmaceuticals (Israel) and Apotex (Canada) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In June 2020 Dr. Reddy's Laboratories released a statement announcing the approval of FDA for Abiraterone Acetate Drugs. The medication is a therapeutic equivalent generic version of Johnson & Johnson's Zytiga, which is used to treat cancer. The introduction of Abiraterone Acetate is a big step forward for the firm.

Market Drivers
  • Increase in Incidence of Prostate Cancer in Men

Market Trend
  • Rapid Development of Prednisolone

Restraints
  • Abiraterone Acetate Drugs have Side Effects such as Chest Pain, Heart Problems, Severe Infections, Broken Bones
  • Abiraterone Acetate Drugs Cannot Fully Cure the Prostate Cancer

Opportunities
Growing Awareness about Abiraterone Acetate Drugs for Metastatic Prostate Cancer
Challenges
Abiraterone Acetate Drugs are Very Expensive and Companies have to comply with FDA Regulation

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Abiraterone Acetate Drugs Study Sheds Light on
— The Abiraterone Acetate Drugs Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Abiraterone Acetate Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Abiraterone Acetate Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By End Users
  • Hospitals
  • Specialized Clinics
  • Diagnostic Centres

By Treatment
  • Chemotherapy
  • Hormone Therapy
  • Clinical Trials
  • Radiotherapy
  • Others

By Distribution Channel
  • Online {Company Website, E-Commerce Website}
  • Offline {Hospital Pharmacy, Retail Stores}

By Dosage Form
  • Film-Coated Tablet
  • Uncoated Tablet

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Incidence of Prostate Cancer in Men
    • 3.3. Market Challenges
      • 3.3.1. Abiraterone Acetate Drugs are Very Expensive
      • 3.3.2. Companies have to comply with FDA Regulation
    • 3.4. Market Trends
      • 3.4.1. Rapid Development of Prednisolone
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Abiraterone Acetate Drugs, by End Users, Treatment, Distribution Channel, Dosage Form and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Abiraterone Acetate Drugs (Value)
      • 5.2.1. Global Abiraterone Acetate Drugs by: End Users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Specialized Clinics
        • 5.2.1.3. Diagnostic Centres
      • 5.2.2. Global Abiraterone Acetate Drugs by: Treatment (Value)
        • 5.2.2.1. Chemotherapy
        • 5.2.2.2. Hormone Therapy
        • 5.2.2.3. Clinical Trials
        • 5.2.2.4. Radiotherapy
        • 5.2.2.5. Others
      • 5.2.3. Global Abiraterone Acetate Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Online {Company Website, E-Commerce Website}
        • 5.2.3.2. Offline {Hospital Pharmacy, Retail Stores}
      • 5.2.4. Global Abiraterone Acetate Drugs by: Dosage Form (Value)
        • 5.2.4.1. Film-Coated Tablet
        • 5.2.4.2. Uncoated Tablet
      • 5.2.5. Global Abiraterone Acetate Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Abiraterone Acetate Drugs (Price)
  • 6. Abiraterone Acetate Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dr. Reddy's Laboratories (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sigma-Aldrich (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ScinoPharm (Taiwan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceuticals (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Apotex (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Abiraterone Acetate Drugs Sale, by End Users, Treatment, Distribution Channel, Dosage Form and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Abiraterone Acetate Drugs (Value)
      • 7.2.1. Global Abiraterone Acetate Drugs by: End Users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Specialized Clinics
        • 7.2.1.3. Diagnostic Centres
      • 7.2.2. Global Abiraterone Acetate Drugs by: Treatment (Value)
        • 7.2.2.1. Chemotherapy
        • 7.2.2.2. Hormone Therapy
        • 7.2.2.3. Clinical Trials
        • 7.2.2.4. Radiotherapy
        • 7.2.2.5. Others
      • 7.2.3. Global Abiraterone Acetate Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Online {Company Website, E-Commerce Website}
        • 7.2.3.2. Offline {Hospital Pharmacy, Retail Stores}
      • 7.2.4. Global Abiraterone Acetate Drugs by: Dosage Form (Value)
        • 7.2.4.1. Film-Coated Tablet
        • 7.2.4.2. Uncoated Tablet
      • 7.2.5. Global Abiraterone Acetate Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Abiraterone Acetate Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Abiraterone Acetate Drugs: by End Users(USD Million)
  • Table 2. Abiraterone Acetate Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 3. Abiraterone Acetate Drugs Specialized Clinics , by Region USD Million (2015-2020)
  • Table 4. Abiraterone Acetate Drugs Diagnostic Centres , by Region USD Million (2015-2020)
  • Table 5. Abiraterone Acetate Drugs: by Treatment(USD Million)
  • Table 6. Abiraterone Acetate Drugs Chemotherapy , by Region USD Million (2015-2020)
  • Table 7. Abiraterone Acetate Drugs Hormone Therapy , by Region USD Million (2015-2020)
  • Table 8. Abiraterone Acetate Drugs Clinical Trials , by Region USD Million (2015-2020)
  • Table 9. Abiraterone Acetate Drugs Radiotherapy , by Region USD Million (2015-2020)
  • Table 10. Abiraterone Acetate Drugs Others , by Region USD Million (2015-2020)
  • Table 11. Abiraterone Acetate Drugs: by Distribution Channel(USD Million)
  • Table 12. Abiraterone Acetate Drugs Online {Company Website, E-Commerce Website} , by Region USD Million (2015-2020)
  • Table 13. Abiraterone Acetate Drugs Offline {Hospital Pharmacy, Retail Stores} , by Region USD Million (2015-2020)
  • Table 14. Abiraterone Acetate Drugs: by Dosage Form(USD Million)
  • Table 15. Abiraterone Acetate Drugs Film-Coated Tablet , by Region USD Million (2015-2020)
  • Table 16. Abiraterone Acetate Drugs Uncoated Tablet , by Region USD Million (2015-2020)
  • Table 17. South America Abiraterone Acetate Drugs, by Country USD Million (2015-2020)
  • Table 18. South America Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 19. South America Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 20. South America Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 21. South America Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 22. Brazil Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 23. Brazil Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 24. Brazil Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 25. Brazil Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 26. Argentina Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 27. Argentina Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 28. Argentina Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 29. Argentina Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 30. Rest of South America Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 31. Rest of South America Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 32. Rest of South America Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 33. Rest of South America Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 34. Asia Pacific Abiraterone Acetate Drugs, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 36. Asia Pacific Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 37. Asia Pacific Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 38. Asia Pacific Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 39. China Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 40. China Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 41. China Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 42. China Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 43. Japan Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 44. Japan Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 45. Japan Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 46. Japan Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 47. India Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 48. India Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 49. India Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 50. India Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 51. South Korea Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 52. South Korea Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 53. South Korea Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. South Korea Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 55. Australia Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 56. Australia Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 57. Australia Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 58. Australia Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 63. Europe Abiraterone Acetate Drugs, by Country USD Million (2015-2020)
  • Table 64. Europe Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 65. Europe Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 66. Europe Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 67. Europe Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 68. Germany Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 69. Germany Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 70. Germany Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 71. Germany Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 72. France Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 73. France Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 74. France Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 75. France Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 76. Italy Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 77. Italy Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 78. Italy Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 79. Italy Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 80. United Kingdom Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 81. United Kingdom Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 82. United Kingdom Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 83. United Kingdom Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 84. Netherlands Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 85. Netherlands Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 86. Netherlands Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 87. Netherlands Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 88. Rest of Europe Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 89. Rest of Europe Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 90. Rest of Europe Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 91. Rest of Europe Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 92. MEA Abiraterone Acetate Drugs, by Country USD Million (2015-2020)
  • Table 93. MEA Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 94. MEA Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 95. MEA Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 96. MEA Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 97. Middle East Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 98. Middle East Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 99. Middle East Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 100. Middle East Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 101. Africa Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 102. Africa Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 103. Africa Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 104. Africa Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 105. North America Abiraterone Acetate Drugs, by Country USD Million (2015-2020)
  • Table 106. North America Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 107. North America Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 108. North America Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 109. North America Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 110. United States Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 111. United States Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 112. United States Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 113. United States Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 114. Canada Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 115. Canada Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 116. Canada Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 117. Canada Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 118. Mexico Abiraterone Acetate Drugs, by End Users USD Million (2015-2020)
  • Table 119. Mexico Abiraterone Acetate Drugs, by Treatment USD Million (2015-2020)
  • Table 120. Mexico Abiraterone Acetate Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 121. Mexico Abiraterone Acetate Drugs, by Dosage Form USD Million (2015-2020)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Abiraterone Acetate Drugs: by End Users(USD Million)
  • Table 133. Abiraterone Acetate Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 134. Abiraterone Acetate Drugs Specialized Clinics , by Region USD Million (2021-2026)
  • Table 135. Abiraterone Acetate Drugs Diagnostic Centres , by Region USD Million (2021-2026)
  • Table 136. Abiraterone Acetate Drugs: by Treatment(USD Million)
  • Table 137. Abiraterone Acetate Drugs Chemotherapy , by Region USD Million (2021-2026)
  • Table 138. Abiraterone Acetate Drugs Hormone Therapy , by Region USD Million (2021-2026)
  • Table 139. Abiraterone Acetate Drugs Clinical Trials , by Region USD Million (2021-2026)
  • Table 140. Abiraterone Acetate Drugs Radiotherapy , by Region USD Million (2021-2026)
  • Table 141. Abiraterone Acetate Drugs Others , by Region USD Million (2021-2026)
  • Table 142. Abiraterone Acetate Drugs: by Distribution Channel(USD Million)
  • Table 143. Abiraterone Acetate Drugs Online {Company Website, E-Commerce Website} , by Region USD Million (2021-2026)
  • Table 144. Abiraterone Acetate Drugs Offline {Hospital Pharmacy, Retail Stores} , by Region USD Million (2021-2026)
  • Table 145. Abiraterone Acetate Drugs: by Dosage Form(USD Million)
  • Table 146. Abiraterone Acetate Drugs Film-Coated Tablet , by Region USD Million (2021-2026)
  • Table 147. Abiraterone Acetate Drugs Uncoated Tablet , by Region USD Million (2021-2026)
  • Table 148. South America Abiraterone Acetate Drugs, by Country USD Million (2021-2026)
  • Table 149. South America Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 150. South America Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 151. South America Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 152. South America Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 153. Brazil Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 154. Brazil Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 155. Brazil Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 156. Brazil Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 157. Argentina Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 158. Argentina Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 159. Argentina Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 160. Argentina Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 161. Rest of South America Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 162. Rest of South America Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 163. Rest of South America Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 164. Rest of South America Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 165. Asia Pacific Abiraterone Acetate Drugs, by Country USD Million (2021-2026)
  • Table 166. Asia Pacific Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 167. Asia Pacific Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 168. Asia Pacific Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 169. Asia Pacific Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 170. China Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 171. China Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 172. China Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 173. China Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 174. Japan Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 175. Japan Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 176. Japan Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 177. Japan Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 178. India Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 179. India Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 180. India Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 181. India Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 182. South Korea Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 183. South Korea Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 184. South Korea Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 185. South Korea Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 186. Australia Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 187. Australia Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 188. Australia Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 189. Australia Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 190. Rest of Asia-Pacific Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 191. Rest of Asia-Pacific Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 192. Rest of Asia-Pacific Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 193. Rest of Asia-Pacific Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 194. Europe Abiraterone Acetate Drugs, by Country USD Million (2021-2026)
  • Table 195. Europe Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 196. Europe Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 197. Europe Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 198. Europe Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 199. Germany Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 200. Germany Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 201. Germany Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 202. Germany Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 203. France Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 204. France Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 205. France Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 206. France Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 207. Italy Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 208. Italy Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 209. Italy Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 210. Italy Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 211. United Kingdom Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 212. United Kingdom Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 213. United Kingdom Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 214. United Kingdom Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 215. Netherlands Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 216. Netherlands Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 217. Netherlands Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 218. Netherlands Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 219. Rest of Europe Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 220. Rest of Europe Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 221. Rest of Europe Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 222. Rest of Europe Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 223. MEA Abiraterone Acetate Drugs, by Country USD Million (2021-2026)
  • Table 224. MEA Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 225. MEA Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 226. MEA Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 227. MEA Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 228. Middle East Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 229. Middle East Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 230. Middle East Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 231. Middle East Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 232. Africa Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 233. Africa Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 234. Africa Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 235. Africa Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 236. North America Abiraterone Acetate Drugs, by Country USD Million (2021-2026)
  • Table 237. North America Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 238. North America Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 239. North America Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 240. North America Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 241. United States Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 242. United States Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 243. United States Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 244. United States Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 245. Canada Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 246. Canada Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 247. Canada Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 248. Canada Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 249. Mexico Abiraterone Acetate Drugs, by End Users USD Million (2021-2026)
  • Table 250. Mexico Abiraterone Acetate Drugs, by Treatment USD Million (2021-2026)
  • Table 251. Mexico Abiraterone Acetate Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 252. Mexico Abiraterone Acetate Drugs, by Dosage Form USD Million (2021-2026)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Abiraterone Acetate Drugs: by End Users USD Million (2015-2020)
  • Figure 5. Global Abiraterone Acetate Drugs: by Treatment USD Million (2015-2020)
  • Figure 6. Global Abiraterone Acetate Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Abiraterone Acetate Drugs: by Dosage Form USD Million (2015-2020)
  • Figure 8. South America Abiraterone Acetate Drugs Share (%), by Country
  • Figure 9. Asia Pacific Abiraterone Acetate Drugs Share (%), by Country
  • Figure 10. Europe Abiraterone Acetate Drugs Share (%), by Country
  • Figure 11. MEA Abiraterone Acetate Drugs Share (%), by Country
  • Figure 12. North America Abiraterone Acetate Drugs Share (%), by Country
  • Figure 13. Global Abiraterone Acetate Drugs share by Players 2020 (%)
  • Figure 14. Global Abiraterone Acetate Drugs share by Players (Top 3) 2020(%)
  • Figure 15. Global Abiraterone Acetate Drugs share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 19. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 21. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 22. Dr. Reddy's Laboratories (India) Revenue: by Geography 2020
  • Figure 23. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 24. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2020
  • Figure 25. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sigma-Aldrich (United States) Revenue: by Geography 2020
  • Figure 27. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 29. Cipla Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. Cipla Ltd. (India) Revenue: by Geography 2020
  • Figure 31. ScinoPharm (Taiwan) Revenue, Net Income and Gross profit
  • Figure 32. ScinoPharm (Taiwan) Revenue: by Geography 2020
  • Figure 33. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 35. Apotex (Canada) Revenue, Net Income and Gross profit
  • Figure 36. Apotex (Canada) Revenue: by Geography 2020
  • Figure 37. Global Abiraterone Acetate Drugs: by End Users USD Million (2021-2026)
  • Figure 38. Global Abiraterone Acetate Drugs: by Treatment USD Million (2021-2026)
  • Figure 39. Global Abiraterone Acetate Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 40. Global Abiraterone Acetate Drugs: by Dosage Form USD Million (2021-2026)
  • Figure 41. South America Abiraterone Acetate Drugs Share (%), by Country
  • Figure 42. Asia Pacific Abiraterone Acetate Drugs Share (%), by Country
  • Figure 43. Europe Abiraterone Acetate Drugs Share (%), by Country
  • Figure 44. MEA Abiraterone Acetate Drugs Share (%), by Country
  • Figure 45. North America Abiraterone Acetate Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche Holding AG (Switzerland)
  • Merck & Co. (United States)
  • Dr. Reddy's Laboratories (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Sigma-Aldrich (United States)
  • Johnson & Johnson (United States)
  • Cipla Ltd. (India)
  • ScinoPharm (Taiwan)
  • Teva Pharmaceuticals (Israel)
  • Apotex (Canada)
Additional players considered in the study are as follows:
Avalon Pharma Pvt Ltd (India) , Mylan (United States) , Hikma Pharmaceuticals USA (United States)
Select User Access Type

Key Highlights of Report


Oct 2021 210 Pages 58 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Abiraterone Acetate Drugs Market Quantitative research analysis
Global Abiraterone Acetate Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Abiraterone Acetate Drugs Market are Roche Holding AG (Switzerland), Merck & Co. (United States), Dr. Reddy's Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), Sigma-Aldrich (United States), Johnson & Johnson (United States), Cipla Ltd. (India), ScinoPharm (Taiwan), Teva Pharmaceuticals (Israel) and Apotex (Canada) etc.
Abiraterone is a drug that is used in conjunction with prednisone to treat prostate cancer that has progressed to other areas of the body. Androgen biosynthesis inhibitors, such as abiraterone, are a kind of drug. It works by lowering the body's level of specific hormones. It is used in the treatment of metastatic castration-resistant prostate cancer and metastatic high-risk castration sensitive prostate cancer in combination with a corticosteroid. It should be administered either after the testicles have been removed or in conjunction with a gonadotropin-releasing hormone mimic.

Know More About Global Abiraterone Acetate Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Primary Hepatocytes Comprehensive Study by Type (Human Primary Cells, Animal Primary Cells), End-Use Industry (Hospitals, Clinic Centre, Pharmaceuticals, Research institutes, Diagnostics laboratories...
$ 3500
Nephro Genetic Testing Comprehensive Study by Test (Blood Tests, Urine Tests), End-Use Industries (Hospitals, Clinic Centre, Pharmaceuticals, Research institutes, Diagnostics laboratories), Diagnos...
$ 3450
Long Acting Drug Delivery Comprehensive Study by Injectable (Sterile Liquid and Powder Filling, Lyophilization, Homogenization, Spray Drying), End-Use Industries (Pharmaceuticals, Clinical, Medical ...
$ 3750
Amoxicillin Drug Comprehensive Study by Type (Tablet, Powder for Suspension, Chewable Tablet, Extended Release Tablet, Capsule), Sales Channels (Online Sales Channel {Company Website, E-Commerce Plat...
$ 3750
Zinc Finger Nuclease Technology Comprehensive Study by Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others), End-User (Biotechnology Companies, Pharmaceu...
$ 3450
Valsartan Tablets Comprehensive Study by Application (Hypertension, Heart Failure, Heart Attack), Category (Adult, Pediatric), Dose (40mg, 80mg, 160mg, 320mg), End-user (Hospital, Clinic, Recovery ...
$ 3500